OBJECTIVE: To determine the impact of initial FDG PET/CT staging on clinical stage and the management plan in patients with locally advanced head and neck cancer (LAHNC). MATERIALS AND METHODS: We retrospectively reviewed the records of 72 consecutive patients (2007-2010) staged with PET/CT and conventional CT with tumours of hypopharynx/larynx (26 patients, 36 %), oral cavity (17 patients, 24 %), oropharynx (16 patients, 22 %), nasopharynx (12 patients, 17 %), and others (2 %). The impact of PET/CT on management plans was considered high when PET/CT changed the planned treatment modality or treatment intent, and intramodality changes were considered as minor changes with low impact. RESULTS: FDG PET/CT changed the stage in 27 patients and had high impact on the management plan in 12 % of patients (detection of distant metastases in 6 patients and stage II in 2 patients). Intramodality changes were more frequent: FDG PET/CT altered the TNM stage in 18/72 (25 %) of patients, upstaging N stage in 90 % of patients with low impact. CONCLUSIONS: Initial FDG PET/CT staging not only improves stage but also affects the management plan in LAHNC patients.
OBJECTIVE: To determine the impact of initial FDG PET/CT staging on clinical stage and the management plan in patients with locally advanced head and neck cancer (LAHNC). MATERIALS AND METHODS: We retrospectively reviewed the records of 72 consecutive patients (2007-2010) staged with PET/CT and conventional CT with tumours of hypopharynx/larynx (26 patients, 36 %), oral cavity (17 patients, 24 %), oropharynx (16 patients, 22 %), nasopharynx (12 patients, 17 %), and others (2 %). The impact of PET/CT on management plans was considered high when PET/CT changed the planned treatment modality or treatment intent, and intramodality changes were considered as minor changes with low impact. RESULTS: FDG PET/CT changed the stage in 27 patients and had high impact on the management plan in 12 % of patients (detection of distant metastases in 6 patients and stage II in 2 patients). Intramodality changes were more frequent: FDG PET/CT altered the TNM stage in 18/72 (25 %) of patients, upstaging N stage in 90 % of patients with low impact. CONCLUSIONS: Initial FDG PET/CT staging not only improves stage but also affects the management plan in LAHNC patients.
Authors: I Kolarova; J Vanasek; V Kandrnal; K Odrazka; L Dusek; V Chrobok; O Belohlavek; M Dolezel; L Petruzelka; R Michalek; J Jarkovsky Journal: Neoplasma Date: 2012 Impact factor: 2.575
Authors: Satoshi Takeuchi; Benjapa Khiewvan; Patricia S Fox; Stephen G Swisher; Eric M Rohren; Roland L Bassett; Homer A Macapinlac Journal: Eur J Nucl Med Mol Imaging Date: 2014-01-18 Impact factor: 9.236
Authors: R J Wong; D T Lin; H Schöder; S G Patel; M Gonen; S Wolden; D G Pfister; J P Shah; S M Larson; D H Kraus Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: Sandro V Porceddu; Elizabeth Jarmolowski; Rodney J Hicks; Rob Ware; LeAnn Weih; Danny Rischin; June Corry; Lester J Peters Journal: Head Neck Date: 2005-03 Impact factor: 3.147
Authors: Andrew M Scott; Dishan H Gunawardana; Dylan Bartholomeusz; Jayne E Ramshaw; Peter Lin Journal: J Nucl Med Date: 2008-09-15 Impact factor: 10.057
Authors: G Paone; F Martucci; V Espeli; L Ceriani; G Treglia; T Ruberto; A Richetti; R Piantanida; L Giovanella Journal: Contrast Media Mol Imaging Date: 2019-09-11 Impact factor: 3.161